Eagle Genomics, a developer of AI-enabled data-driven microbiome discovery software platform, has closed $9 million in new scale-up funding. The consortium, led by Granpool Innovative Investments, includes bpd partners, Anatom Holding and Albert-László Barabási led the funding round.
The company plans to use the new funds to develop its AI-augmented, knowledge discovery platform and drive further commercial expansion across Europe and the US.
According to the company, its knowledge discovery platform harnesses AI to analyze complex genomic and microbiome data at scale, delivering new insight and allowing the enterprises to assess the viability, efficacy, and safety of products.
Many brands, including Unilever, use the platform to harnesses genomic and microbiome data at scale. Unilever uses the platform to distill scientific evidence to support claims about its Zendium toothpaste, which uses natural enzymes to boost the good bacteria in the mouth – the first substantiated microbiome-based claim recorded in a product launch, the company said.
“The microbiome is a megatrend that is evolving very quickly, and we are at the forefront of associated discovery with our unique solution to address the enterprise data challenges. We have our sights set too on other complex data challenges, including CRISPR and quantum biological challenges, such as understanding the immune response more fully. The potential is phenomenal, and we are immensely grateful to our supporters for sharing our vision and helping us to scale at this pivotal time.”
Microbiome-related research is a big business now. Bill Gates has claimed that “Understanding the microbiome is as big a breakthrough as anything else we will do in health over the next two decades.” Eagle Genomics is Microsoft’s first microbiome-focused partner.
Genomics data analytics companies have raised over $1.1 billion in the past five years, according to the Mercom Funding database. Learn More.
